替诺福韦治疗与未治疗的慢性感染母亲及其免疫预防失败婴儿的乙型肝炎病毒特征
研究分析了未治疗(n=89)和替诺福韦酯(TDF)治疗(n=68)的高病毒载量慢性HBV感染母亲及其婴儿的血清HBV DNA。分娩时,TDF治疗母亲HBV DNA滴度较低、基础核心启动子(BCP)突变频率较高,而pre-S/S和pre-core/core突变频率相似。母亲HBV DNA滴度、基因型C和pre-S1野生型序列与婴儿免疫预防失败(IPF)相关。
要点
- 分娩时TDF治疗母亲较未治疗母亲HBV DNA滴度更低、BCP突变频率更高。
- 母亲基因型C和pre-S1野生型序列独立于病毒血症与婴儿IPF相关。
- 携带表面「a」决定簇突变株的母亲所生婴儿似乎受到免疫预防保护。
核心结论
- 除分娩时母亲高HBV DNA滴度外,母亲基因型C和pre-S1野生型序列是婴儿IPF的潜在危险因素,而BCP突变不是。
- 携带「a」决定簇突变株作为主要株的孕妇所生子女似乎受到免疫预防的保护。
研究设计与样本
- 研究纳入未治疗(n=89)和TDF治疗(n=68)的高病毒载量慢性HBV感染母亲及其婴儿,采用巢式PCR和直接测序分析血清HBV DNA。
主要发现
- 分娩时,与未治疗母亲相比,TDF治疗母亲HBV DNA滴度较低、BCP基因突变频率较高,但pre-S/S和pre-core/core突变频率相似。
- 14名携带表面「a」决定簇突变株的母亲未将突变株传播给其免疫预防的婴儿。
- 13名IPF婴儿中3名检出表面「a」决定簇突变株,而这13名母亲均为野生型乙型肝炎表面抗原(HBsAg)。
- 单因素分析显示,分娩时母亲HBV DNA滴度(OR:1.54;95%CI:1.02-2.33;P=0.039)、基因型C(OR:4.18;95%CI:1.28-13.62;P=0.018)和pre-S1野生型序列(OR:6.33;95%CI:1.85-21.68;P=0.003)与婴儿IPF相关。
- 多因素分析显示,母亲基因型C(OR:3.71;95%CI:1.11-12.36;P=0.033)和pre-S1野生型(OR:6.34;95%CI:1.79-22.44;P=0.004)独立于母亲病毒血症与婴儿IPF相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Maternal tenofovir disoproxil fumarate (TDF) therapy during late pregnancy can reduce mother-to-infant transmission of hepatitis B virus (HBV). We investigated HBV mutations associated with maternal TDF therapy and their role in infant immunonophylaxis failure (IPF). METHODS: Serum samples from untreated (n = 89) and TDF-treated (n = 68), highly viremic, chronically infected mothers and their infants were analyzed for HBV DNA by nested polymerase chain reaction (PCR) and direct sequencing. RESULTS: At delivery, compared with untreated mothers, TDF-treated mothers had a lower HBV DNA titer and a higher frequency of basal core promoter (BCP) gene mutations, but they had similar frequencies in pre-S/S and pre-core/core mutations. The 14 mothers harboring surface "a" determinant mutants did not transmit the mutants to their immunized infants. Such mutants were found in 3 of 13 IPF infants; the 13 mothers had wild-type hepatitis B surface antigen (HBsAg). In univariable analysis, maternal HBV DNA titer (odds ratio [OR]: 1.54; 95% confidence intervals [CI]: 1.02-2.33; P = .039), genotype C (OR: 4.18; 95% CI: 1.28-13.62; P = .018) and pre-S1 wild-type sequence (OR: 6.33; 95% CI: 1.85-21.68; P = .003) at delivery were associated with infant IPF. Multivariable analyses showed that maternal genotype C (OR: 3.71; 95% CI: 1.11-12.36; P = .033) and pre-S1 wild-type (OR: 6.34; 95% CI: 1.79-22.44; P = .004) were associated with infant IPF independently of maternal viremia. CONCLUSIONS: Along with high maternal HBV DNA titer at delivery, maternal genotype C and pre-S1 wild-type sequence were potential risk factors for infant IPF, although BCP mutations were not. The offspring of pregnant women harboring "a" determinant mutants as major strains seemed to be protected by immunoprophylaxis. CLINICAL TRIALS REGISTRATION: NCT01312012.
引用
- Hsu HY, Chen HL, Chiang CL, et al. Characterization of Hepatitis B Virus in Tenofovir-Treated and Untreated Chronically Infected Mothers and Their Immunoprophylaxis Failure Infants. Clin Infect Dis. 2023. PMID: 35789261. doi:10.1093/cid/ciac539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。